Published in final edited form as:

Magn Reson Imaging. 2008 July ; 26(6): 721–726. doi:10.1016/j.mri.2008.01.002.

Feasibility of Using Hyperpolarized [1-¹³C]Lactate as a Substrate for In Vivo Metabolic ¹³C MRSI Studies

Albert P. Chen¹, John Kurhanewicz¹, Robert Bok¹, Duan Xu¹, David Joun¹, Vickie Zhang¹, Sarah J. Nelson¹, Ralph E. Hurd², and Daniel B. Vigneron¹

¹Dept. of Radiology, University of California, San Francisco, CA

²GE Healthcare, Menlo Park, CA

Abstract

The development of dynamic nuclear polarization (DNP) in solution has enabled *in vivo* ¹³C MR studies at high signal to noise ratio (SNR) following injection of pre-polarized ¹³C substrates. While prior studies have demonstrated the ability to observe metabolism following injection of hyperpolarized ¹³C-pyruvate, the goal of this study was to develop and test a new hyperpolarized agent for investigating *in vivo* metabolism, [1-¹³C] lactate. A preparation for pre-polarized ¹³C-lactate and the requisite dissolution media were developed to investigate the feasibility for *in vivo* ¹³C MRS/MRSI studies following injection of this hyperpolarized agent. This study demonstrated, for the first time, not only the ability to detect hyperpolarized [1-¹³C] lactate *in vivo*, but also the metabolic products ¹³C pyruvate, ¹³C alanine and ¹³C bicarbonate following injection in normal rats. Using ¹³C-lactate as a substrate provided the ability to study the conversion of lactate to pyruvate *in vivo* and to detect the secondary conversions to alanine and bicarbonate through pyruvate. This study also demonstrated the potential value of this hyperpolarized agent to investigate *in vivo* lactate uptake and metabolism in pre-clinical animal models.

Introduction

Recent studies have demonstrated that signal enhancements from dynamic nuclear polarization (DNP) can be retained in solution (1). This development has enabled *in vivo* ¹³C MR studies at high signal to noise ratio (SNR) following injection of pre-polarized ¹³C substrates (2). It has been shown by using [1-¹³C]pyruvate as the substrate for hyperpolarized ¹³C MRS/MRSI experiment, real time cellular metabolism can be studied in normal and diseased tissues *in vivo* (3–5). These studies have shown the ability to detect the metabolic conversion of the hyperpolarized [1-¹³C]pyruvate into [1-¹³C]lactate, [1-¹³C]alanine and ¹³C-bicarbonate after *in vivo* injection in animal models. In these studies using pre-polarized ¹³C pyruvate as the substrate, the concentration of pyruvate in the injected solution was much higher than the endogenous concentration (3–5). Thus one of the processes that can be probed in these conditions is the cellular conversion of the ¹³C pyruvate bolus to ¹³C lactate (6).

Correspondence to: Dr. Daniel B. Vigneron, Dept of Radiology, Box 2512, University of California, San Francisco, 1700 4th St. QB3 building, suite 102, San Francisco CA, 94158-2512, Phone: (415) 476-3343, Fax: (415) 514-4451, Email: dan.vigneron@radiology.ucsf.edu.

Publisher's Disclaimer: This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final citable form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

All these prior studies (2–6) have used ^{13}C -pyruvic acid, however, if ^{13}C -lactate could be used as the substrate in pre-polarized ^{13}C MRS/MRSI study, it then may be possible to probe the reverse enzymatic conversion of hyperpolarized ^{13}C lactate into the unlabeled pyruvate pool. This could allow better understanding of the lactate dehydrogenase (LDH) activity *in vivo* in different tissue types or diseases at different stages. The development of ^{13}C -lactate as a new hyperpolarized agent for *in vivo* studies requires overcoming several obstacles. $[\text{l-}^{13}\text{C}]\text{Pyruvic-acid}$ is an especially good compound for hyperpolarized studies since as a neat solution it naturally forms an amorphous solid at 1°K , polarizes rapidly to a high percentage in under 1 hour, and retains polarization well due to its long T_1 in solution. For $[\text{l-}^{13}\text{C}]\text{lactate}$, a different preparation is required with a high substrate concentration, a glassing agent/solvent to insure an amorphous solid at 1°K , a short DNP enhancement rate constant and a high degree of polarization. The goal of this study was to develop a hyperpolarized MR probe based on $[\text{l-}^{13}\text{C}]\text{lactate}$ as the substrate for *in vivo* ^{13}C MRS/MRSI studies and to determine if metabolic products could be detected following injection in animal models.

Methods

Polarizer and compound

A HyperSense DNP polarizer (Oxford Instruments, Abingdon, UK) was used in this study. The preparation for pre-polarization developed in this project was a mixture of $[\text{l-}^{13}\text{C}]\text{lactate}$ (Isotec, Miamisburg, OH), water, DMSO and OX63 trityl radical (Oxford Instruments, Abingdon, UK). The mixture contained 38.5 % $^{13}\text{C}_1\text{-lactate}$ and 30% DMSO. The trityl radical concentration was 15 mM. The $[\text{l-}^{13}\text{C}]\text{lactate}$ mixture was polarized in a field of 3.35T at approximately 1.4°K by irradiation of 94.116 GHz microwaves similarly to what was described previously for $[\text{l-}^{13}\text{C}]\text{pyruvate}$ (1). Each sample used in the animal experiments was polarized for ~ 100 minutes prior to dissolution.

A normal saline and 100mg/L sodium EDTA solution was used as the dissolution medium. The ^{13}C -lactate concentration in the hyperpolarized lactate solution was 44 mM. Immediately after the dissolution, an aliquot of the hyperpolarized lactate solution was used to measure the percent polarization (ranging from 6.9 – 12.4%, average 10.0 % for these experiments). The duration for the dissolution process and transferring of the solution was approximately 10 – 15s. In each rat studied, ~2.5 ml (ranging from 2.2 – 3 ml, average 2.6 ml) of the final lactate solution was injected into the rat over a 12 s period followed by a normal saline flush.

Animal Handling

All animal studies were carried out under a protocol approved by the UCSF Institutional Animal Care and Use Committee. Male Sprague-Dawley rats ranging in weight from 250 to 350 grams were placed on a heated pad and anesthetized with isoflurane (2–3%). A catheter was introduced into the tail vein for the eventual intra-venous administration of hyperpolarized lactate solution, and the rat was transferred to a heated pad in the RF coil in the MR scanner. While in the scanner, anesthesia was maintained by a continual delivery of isoflurane (1–2%) via a long tube to a cone placed over the rat's nose and mouth. The rat's vital signs (heart rate and oxygen saturation) were continually monitored. Care was taken to ensure that body temperature was maintained at 37°C throughout the imaging procedures by maintaining a flow of heated water through the pad underneath the rat. At the end of the study, the rat was euthanized by a combination of over-anesthesia with isoflurane and bilateral thoracotomy following an approved protocol.

MRI, MRS, and MRSI studies

All studies were performed using a 3T GE Signa™ scanner (GE Healthcare, Waukesha, WI) equipped with the MNS (multinuclear spectroscopy) hardware package. The RF coil used in

these experiments was a dual-tuned ^1H - ^{13}C coil with a quadrature ^{13}C channel and linear ^1H channel constructed based on an earlier design (7) and used in prior hyperpolarized ^{13}C pyruvate studies (3–5). The inner coil diameter was 8 cm and the length of the coil was 9 cm to accommodate rats of varying size.

T2-weighted anatomical images were obtained in all three planes using a fast spin-echo (FSE) sequence. Axial and sagittal images were each acquired in ~10 minutes with a 10 cm FOV, 192×192 matrix, 2 mm thick slices and NEX = 6. Coronal images were acquired with a 12 cm FOV, 192×192 matrix, 1.5 mm thick slices and NEX = 6 with a scan time of 10 minutes. The total imaging time required to obtain images in all three planes was thus approximately 35 minutes.

One polarized/dissolved sample was used to estimate the T1 relaxation time of the hyperpolarized $[1\text{-}^{13}\text{C}]\text{lactate}$ in solution. The polarized $[1\text{-}^{13}\text{C}]\text{lactate}$ solution was transfer into a syringe and placed inside the dual tuned coil used in this study. A small tip angle, non-localized MRS pulse sequence (identical to what is used in the ^{13}C *in vivo* dynamic MRS study described in the next paragraph) was used to measured the signal decay due to T1 relaxation. A mono-exponential fit was used to estimate the T1 and the reported T1 value was corrected for RF tipping (8).

Five ^{13}C dynamic MRS studies were performed in five different rats using a double spin-echo pulse sequence with a non-selective 5 degree flip angle RF excitation pulse and a pair of 180 degree hyperbolic secant refocusing pulses (also without localization) (4). A TE of 35 ms, a repetition time (TR) of 3 s and a readout filter of 5000 Hz / 2048 pts were used for these studies. The acquisition started at the beginning of a 12-second manual injection of the ^{13}C -lactate into the rat tail vein.

3D ^{13}C MRSI data were acquired in 10 seconds in two normal rats using a double spin-echo pulse sequence with a slice selective small tip angle excitation pulse and a flyback echo-planar readout trajectory (4). A $8 \times 6 \times 1$ phase encoding matrix with flyback echo-planar trajectory on the Z-axis ($8 \times 6 \times 16$ effective matrix) was used with $10 \text{ mm} \times 10 \text{ mm} \times 10 \text{ mm}$ spatial resolution (1.0 cc voxel resolution) that resulted with a $80 \text{ mm} \times 60 \text{ mm} \times 160 \text{ mm}$ FOV to cover the rat torso and abdomen. The flyback echo-planar trajectory was designed for a 581 Hz spectral bandwidth to include ^{13}C lactate, ^{13}C alanine and ^{13}C pyruvate without spectral aliasing. A total of 59 readout/rewind lobes were included during each readout for a spectral resolution of 9.83 Hz. With a readout filter of 25,000 Hz / 2,538 points, 16 k-space points were acquired during each TR and the SNR efficiency of this waveform was 61% (9). The TE for the MRSI acquisition was 140 ms (readout was centered on the center of the second spin-echo), and the TR was 215 ms.

Data processing

Dynamic data were apodized in the time domain with a 10 Hz Gaussian filter prior to a one-dimensional Fourier transform. 3D ^{13}C MRSI data acquired using the flyback echo-planar trajectory were processed using the same procedures described previously (4,9). The k-space points corresponding to the constant portion of the flyback trajectory were selected out and the data was reordered into a 4D dataset with the time decay in the first dimension. The reordered dataset was then processed in the same manner as a conventional 4D MRSI dataset with the exception that the k-space points in the flyback dimension were each acquired at a slightly different time point (9). This was corrected during the 4D Fourier reconstruction using the fact that an origin shift in k-space is equivalent to a phase shift in the transformed domain. The time domain signal was apodized by 16 Hz Gaussian filter and zero-filled from 59 pts to 128 pts. No apodization in the spatial domains was applied.

Results

The T1 of hyperpolarized [1- ^{13}C] lactate estimated from the MRS study performed on the syringe of hyperpolarized lactate solution was 45s. In this experiment, polarization in solution was measured to be ~7%, which corresponds to a 28,500 fold increase in polarization compared to the thermal equilibrium polarization of 2.47ppm at 3T and 300°K.

From the dynamic MRS studies performed starting at the same time as the pre-polarized ^{13}C lactate was injected, the time course of hyperpolarized ^{13}C lactate uptake in the animal, as well as the time course of the formation of its metabolic products were determined. Representative data in figure 1 shows a stacked plot of dynamic ^{13}C data (first 25 time points, each 3 seconds apart) and a graph of the signal amplitude vs time from one of the *in vivo* dynamic studies. Resonances for ^{13}C lactate, ^{13}C alanine, and ^{13}C pyruvate were observed in the spectra (figure 1). In the time course graph in figure 1, the peak amplitudes of ^{13}C alanine and ^{13}C pyruvate were scaled up by 10 fold for easier viewing. Also observed in this graph was that the ^{13}C pyruvate resonance appeared in the dynamic MRS study prior to the appearance of the ^{13}C alanine resonance, but the ^{13}C alanine signal amplitude becomes higher than that of the ^{13}C pyruvate at approximately 15s after the start of the injection/experiment in this particular case. No discernable ^{13}C bicarbonate resonance was observed in this dynamic study. Table 1 summarized the lactate arrival time as well as the lactate, pyruvate and alanine time to peak (maximum amplitude in the time course) relative to the start of the injection time. The alanine time to peak was on average 14.4s after the lactate time to peak and 7.4s after the pyruvate time to peak.

In two out of the five dynamic studies, ^{13}C bicarbonate resonance was observed, the representative data is shown in figure 2. Due to limited SNR of the ^{13}C bicarbonate signal, the ^{13}C bicarbonate peak was more clearly observed in the summed spectrum (figure 2b) as compared the individual spectra in the stacked plot (figure 2a).

From the 3D ^{13}C MRSI studies, high amplitudes of ^{13}C lactate were observed (figure 3), ^{13}C alanine and pyruvate were also observed in voxels centered on rat kidney, muscle and vasculature. Consistent with the data from the ^{13}C dynamic MRS studies, higher ^{13}C alanine signal amplitude compared to that of ^{13}C pyruvate were observed in the MRSI voxels where both resonances were present.

Discussion

Hyperpolarized ^{13}C MRS/MRSI provides an exciting new opportunity to study dynamic metabolic processes *in vivo* since small organic molecules including many metabolic intermediates have the potential to be compatible with the DNP process (3). Oxidation, transamination, and oxidative decarboxylation of pre-polarized [1- ^{13}C]pyruvate to produce ^{13}C lactate, ^{13}C alanine and ^{13}C bicarbonate have been reported *in vivo* (3). Since high, non-physiological concentrations of [1- ^{13}C]pyruvate were used in these studies, this substrate allowed investigation of the differences in the enzymatic conversion of pyruvate to lactate for different tissue types. However, the lactate to pyruvate process could not be studied with ^{13}C -pyruvate as the substrate. Using pre-polarized ^{13}C -lactate as the substrate, provides a new opportunity to probe the LDH activity that converts lactate to pyruvate and to determine if secondary conversions from lactate through pyruvate to alanine and bicarbonate would be observable *in vivo* by hyperpolarized ^{13}C MRSI.

In this study, after injection of the hyperpolarized [1- ^{13}C]lactate into rats, ^{13}C pyruvate was indeed observed (figure 1–3). In addition, ^{13}C alanine resonance was also observed in these experiments. The spectral pattern observed in these studies were very different from that observed in the studies in which [1- ^{13}C]pyruvate was injected. The alanine signal intensity

was higher than the signal intensity for pyruvate in both the dynamic MRS studies as well as the MRSI studies. It can be surmised that the ^{13}C pyruvate produced by the ^{13}C lactate substrate was rapidly consumed to produce lactate, alanine and bicarbonate, resulting in the relatively low level of ^{13}C pyruvate. The slight temporal offset between ^{13}C pyruvate curve and ^{13}C alanine curve in figure 1 (pyruvate signal was higher initially compared to that of alanine) and the delayed time to peak of the lactate seen in the dynamic MRS studies (figure 1, table 1) further suggest that ^{13}C pyruvate was produced first after the injection of the ^{13}C lactate, and the ^{13}C pyruvate was then metabolized to ^{13}C alanine, ^{13}C bicarbonate, and perhaps back to ^{13}C lactate. It is worth noting that while the pre-polarized magnetization may have been decreased through T1 losses in various enzymatic and membrane transport processes, ^{13}C bicarbonate was still observable in some cases through three enzyme catalyzed reactions (lactate dehydrogenase, pyruvate dehydrogenase and carbonic anhydrase). The fact that multiple down stream products from ^{13}C lactate was observed in this study demonstrates the added potential of using pre-polarized ^{13}C substrates for *in vivo* metabolic studies in which multiple enzyme steps are required.

In the MRSI experiments performed in this study, high intensity ^{13}C lactate signals were observed in most voxels within the body of the rat. ^{13}C pyruvate and ^{13}C alanine were observed mostly in the kidney and the muscle/central vasculature regions in the rat body. It appeared that the uptake of lactate did not differ significantly between different tissues in a normal healthy rat. The low amplitudes of the ^{13}C pyruvate and ^{13}C alanine signals observed in these studies relative to the ^{13}C lactate signal indicate that the conversion of the ^{13}C lactate to pyruvate is fairly low in normal tissues. More ^{13}C pyruvate and alanine were detected in voxels containing rat kidney, but with the low signal level of these metabolic products and the large voxel sizes used, it was not possible to see clear differences in metabolic activities between different tissue types in this study. Further more, the flyback echo-planar readout trajectory didn't have adequate spectral bandwidth to include the ^{13}C bicarbonate resonance without spectral aliasing. And base on the relative SNR of the ^{13}C bicarbonate compare to the other metabolites, the ^{13}C bicarbonate signal was most likely below the detection limit in these 3D MRSI experiments. To allow observation of ^{13}C bicarbonate, perhaps a 2D MRSI experiment (5) without using the flyback readout trajectory (to give larger spectral bandwidth), and larger voxel size (to give more SNR) are required.

In all the *in vivo* experiments reported in this study, the boluses given corresponded to an approximate 5–6 mM concentration of ^{13}C lactate in blood of the animals. This concentration is 4–5 times the endogenous blood lactate concentration in a resting animal (1 – 2 mM) but within physiological range for an exercising mammal. Thus the results of this study demonstrate the feasibility for studying hyperpolarized lactate metabolism at concentrations within the physiological range for blood lactate levels.

A prior study using hyperpolarized pyruvate reported that higher levels of ^{13}C lactate were observed in regions of prostate cancer in a mouse model of prostate cancer after injection of pre-polarized ^{13}C pyruvate (4). But it was not clear that if the high level of lactate observed in the tumor reflected solely the higher level of LDH activity within the tumor, or higher uptake of the ^{13}C lactate (produced in the blood and other organs) as well. Although beyond the scope of this initial feasibility study, using pre-polarized ^{13}C lactate as a substrate for *in vivo* MRSI studies may allow improved elucidation of the mechanism behind the high lactate observed in region of tumor in pre-clinical cancer models.

Conclusions

The feasibility of using $[1-^{13}\text{C}]$ lactate as a substrate for pre-polarized MRS and MRSI *in vivo* was demonstrated in this study. The metabolic products ^{13}C pyruvate, ^{13}C alanine and ^{13}C

bicarbonate were observed in normal rats following injection of hyperpolarized ^{13}C lactate. Using $[\text{l-}^{13}\text{C}]\text{lactate}$ as a substrate provides the opportunity to study the conversion of lactate to pyruvate *in vivo* and to detect the secondary conversions to alanine and bicarbonate through pyruvate.

Reference

1. Ardenkjaer-Larsen JH, Fridlund B, Gram A, Hansson G, Hansson L, Lerche MH, Servin R, Thaning M, Golman K. Increase in signal-to-noise ratio of > 10,000 times in liquid-state NMR. *Proc Natl Acad Sci U S A* 2003;100(18):10158–10163. [PubMed: 12930897]
2. Golman K, Ardenkjaer-Larsen JH, Peterson JS, Mansson S, Leunbach I. Molecular Imaging with endogenous substances. *Proc Natl Acad Sci U S A* 2003;100(18):10435–10439. [PubMed: 12930896]
3. Golman K, Zandt R, Thaning M. Real-time metabolic imaging. *PNAS* 2006;103(30):11270–11275. [PubMed: 16837573]
4. Chen AP, Alberts MJ, Cunningham CH, Kohler SJ, Yen Y, Hurd RE, Tropp J, Bok R, Pauly JM, Nelson SJ, Kurhanewicz J, Vigneron DB. Hyperpolarized C-13 Spectroscopic Imaging of the TRAMP Mouse at 3T – Initial Experience. *Magn Reson Med*. In-Press.
5. Kohler SJ, Yen Y, Wolber J, Chen AP, Albers MJ, Bok R, Zhang V, Tropp J, Nelson S, Vigneron DB, Kurhanewicz J, Hurd RE. In vivo ^{13}C carbon metabolic imaging at 3T with hyperpolarized ^{13}C -1-pyruvate. *Mag Res Med* 2007;58(1):65–69.
6. Zierhut, ML.; Chen, AP.; Bok, R.; Albers, M.; Zhang, V.; Pels, P.; Tropp, J.; Park, I.; Vigneron, DB.; J, K.; Hurd, R.; Nelson, SJ.; Yen, Y. Kinetic Modeling of Hyperpolarized ^{13}C -1-Pyruvate Metabolism Using Dynamic Magnetic Resonance Spectroscopy; International Society for Magnetic Resonance In Medicine 15th annual meeting; Berlin, Germany. 2007. p. 366
7. Derby K, Tropp J, Hawryszko C. Design and Evaluation of a Novel Dual-Tuned Resonator for Spectroscopic Imaging. *J Mag Reson* 1990;86:645–651.
8. Deichmann R, Hahn D, Haase A. Fast T1 Mapping on a Whole-Body Scanner. *Mag Res Med* 1999;42:206–209.
9. Cunningham C, Vigneron D, Chen A, Xu D, Nelson S, Hurd R, Kelley D, Pauly J. Design of flyback echo-planar readout gradients for magnetic resonance spectroscopic imaging. *Mag Res Med* 2005;54:1286–1289.

Rat C13 lactate dynamic study (non-localized)

Figure 1.

Dynamic MRS data from a normal rat after injection of hyperpolarized ^{13}C lactate. Both a stacked plot of individual spectra from each time points (first 25 time points, top right) and a time course graph (bottom left) of the ^{13}C lactate, ^{13}C alanine and ^{13}C pyruvate peak amplitude were shown.

Figure 2.

Stacked plot of in vivo dynamic MRS spectra (first 16 time points, a) as well as a summed spectrum from the stacked shown (b). In addition to the ^{13}C lactate, alanine and pyruvate resonances, the ^{13}C bicarbonate resonance was also observed.

Figure 3. Axial T2-weighted anatomical image (left) from a rat through one of the kidneys as well as the corresponding ^{13}C MRSI data (right) are shown. High level of ^{13}C lactate signal was observed throughout the slice, ^{13}C alanine and pyruvate resonances were observed in voxels containing kidney and voxels containing muscle and vasculature.

Table 1

Summary of C-13 Lactate Dynamic MRS Data

Rat #	Animal Weight (kg)	Dose* (mg/kg)	Lactate Arrival Time (s)	Lactate Time To Peak (s)	Pyruvate Time To Peak (s)	Alanine Time To Peak (s)
1	0.31	34.9	0	9	15	21
2	0.36	30.0	3	9	18	27
3	0.36	24.5	0	12	18	27
4	0.32	31.3	0	12	18	24
5	0.33	29.1	3	12	20	27
mean	0.34	30.0	1.2	10.8	17.8	25.2

* Injected solution was 44mM lactate yielding an estimated 5–6mM blood concentration.